Peter Ansell, Ph.D., Scientific Director and Research Fellow, Precision Medicine Oncology at AbbVie discussed how his team overcame many challenges they have previously faced using FFPE clinical samples by integrating HTG’s innovative HTG Transcriptome Panel (HTP) into their biomarker strategies.
News & Events
AACR Annual Meeting 2023
April 14-19, 2023 | Join us at the AACR Annual Meeting in Orlando, FL
- Category:
- Future Events
HTG Provides a Year-End Update on its Drug Discovery Business and Attends LifeSci Partners 2023 Corporate Access Event
TUCSON, Ariz. , Jan. 09, 2023 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today provided an update on the progress of…
- Category:
- Press Releases
HTG Announces Certain Preliminary 2022 Unaudited Financial Results
Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz. , Jan. 06, 2023 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its…
- Category:
- Press Releases
HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series
TUCSON, Ariz. , Dec. 28, 2022 (GLOBE NEWSWIRE) – HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, provides here a summary of its second HTG…
- Category:
- Press Releases
Publications
Read white papers or journal publications and view other scientific content.
Careers at HTG
At HTG, we are always looking for talented individuals to help us deliver our next-generation sequencing-based products throughout the world.
New Careers
Page last updated March 14, 2023